.After a handful of years in biotech, Mike Quigley, Ph.D., is actually coming back to the pharma layer, using up the best science location at Sanofi.Quigley will certainly start Sept. 30 as the French Big Pharma’s primary clinical officer as well as worldwide head of analysis, Sanofi informed Fierce Biotech in an emailed statement.Quigley is actually switching out Frank Nestle, M.D., that left Sanofi this spring in the middle of a global overhaul of the company’s R&D device. Nestle, who devoted eight years along with the pharma, jumped over to Deerfield Management, where he presently works as a partner on the therapies group and CEO of the agency’s curative revelation as well as advancement procedures.
Quigley will certainly join Sanofi from a San Francisco-based biotech that’s in stealth, depending on to his LinkedIn profile. He’s presently provided as the business’s founder, head of state and also chief executive officer.Since August 2021, Quigley has actually acted as a venture companion at SV Health Investors, a health care fund manager along with current financial investments in biotechs like BioAge, Cerevance, Dualitas Therapies and Nimbus Rehabs, among others. Quigley formerly stored the top area at Dualitas, a biotech that stays in stealth, according to STAT.The prospective Sanofi forerunner likewise earlier helmed Therini Bio, an immunotherapy biotech working to cultivate procedures for neurodegenerative conditions driven by general problems.Just before devoting the last few years in biotech, Quigley possesses an also longer track record in Significant Pharma, very most recently acting as Gilead’s elderly vice president of analysis biology until the summer of 2021.
Before that, he appeared more than 4 years throughout a variety of leadership tasks at Bristol Myers Squibb and also acted as a scientific supervisor at Johnson & Johnson’s Janssen arm before that.Sanofi claimed Quigley’s objective in his brand new role would be actually to “maximize our likelihood of results via superior collaborations around our organization and also past, delivering best-in-class development as well as cultivating and sourcing brand new industry-leading talent along with a commitment to diversity,” depending on to an interior memo obtained by STAT.